PLIANT THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.81 USD | -0.59% |
|
-5.67% | -34.79% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 806.1 | 486.5 | 942.5 | 1,085 | 712.4 | - | - |
| Enterprise Value (EV) 1 | 806.1 | 486.5 | 621.3 | 600.5 | 350.4 | 335.6 | 423.7 |
| P/E ratio | -11.7 x | -4.98 x | -6.57 x | -6.59 x | -3.59 x | -3.27 x | -3.07 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 19.3 x | 64.3 x | 97.3 x | 687 x | 462 x | 123 x | 214 x |
| EV / Revenue | 19.3 x | 64.3 x | 64.1 x | 380 x | 227 x | 57.7 x | 127 x |
| EV / EBITDA | - | - | -4.96 x | -3.29 x | -1.61 x | -1.36 x | -1.46 x |
| EV / FCF | -20.8 x | -6.29 x | -6.45 x | -5.12 x | -2 x | -1.72 x | -1.83 x |
| FCF Yield | -4.81% | -15.9% | -15.5% | -19.5% | -50% | -58.2% | -54.5% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 35,480 | 36,039 | 48,759 | 59,896 | 60,319 | - | - |
| Reference price 2 | 22.72 | 13.50 | 19.33 | 18.11 | 11.81 | 11.81 | 11.81 |
| Announcement Date | 3/16/21 | 2/28/22 | 3/9/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 41.82 | 7.572 | 9.685 | 1.58 | 1.541 | 5.814 | 3.325 |
| EBITDA 1 | - | - | -125.4 | -182.3 | -218.1 | -245.9 | -290.3 |
| EBIT 1 | -41.64 | -19.99 | -127.2 | -184.1 | -209.5 | -244.3 | -275.2 |
| Operating Margin | -99.59% | -263.95% | -1,313.37% | -11,654.75% | -13,593.27% | -4,202.35% | -8,275.81% |
| Earnings before Tax (EBT) 1 | -41.53 | -19.71 | -123.3 | -161.3 | -203.2 | -246.7 | -276.1 |
| Net income 1 | -41.53 | -19.71 | -123.3 | -161.3 | -201.1 | -240.6 | -270.9 |
| Net margin | -99.32% | -260.35% | -1,273.32% | -10,211.14% | -13,048.61% | -4,138.03% | -8,147.07% |
| EPS 2 | -1.950 | -2.710 | -2.940 | -2.750 | -3.294 | -3.612 | -3.849 |
| Free Cash Flow 1 | -38.8 | -77.4 | -96.39 | -117.3 | -175.2 | -195.2 | -230.9 |
| FCF margin | -92.79% | -1,022.13% | -995.26% | -7,422.91% | -11,363.63% | -3,357.46% | -6,944.19% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 3/16/21 | 2/28/22 | 3/9/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.61 | 1.999 | 1.249 | 4.989 | 1.482 | 1.965 | 1.332 | 0.248 | - | - | 0.3871 | 0.3871 | 0.3871 | 0.6371 | 0.5 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | -50 | -53 | -58 | -63 | - |
| EBIT 1 | -27.11 | -24.6 | -28.21 | -29.64 | -31.95 | -37.4 | -42.1 | -47.33 | -47.68 | -47.04 | -49.06 | -51.49 | -53.89 | -56.03 | -61.05 |
| Operating Margin | -1,684.04% | -1,230.57% | -2,258.69% | -594.15% | -2,155.67% | -1,903.31% | -3,160.29% | -19,083.87% | - | - | -12,674.71% | -13,303.39% | -13,922.92% | -8,794.21% | -12,210.5% |
| Earnings before Tax (EBT) 1 | -27.04 | -24.53 | -28.1 | -29.55 | -30.62 | -35.06 | -37.55 | -41.19 | -41.49 | -41.11 | -46.67 | -49.74 | -52.55 | -54.9 | -59.06 |
| Net income 1 | -27.04 | -24.53 | -28.1 | -29.55 | -30.62 | -35.06 | -37.55 | -41.19 | -41.49 | -41.11 | -46.47 | -49.19 | -51.78 | -53.61 | -59.06 |
| Net margin | -1,679.81% | -1,227.16% | -2,249.8% | -592.22% | -2,065.79% | -1,784.22% | -2,818.92% | -16,609.68% | - | - | -12,006.02% | -12,708.34% | -13,376.65% | -8,415.71% | -11,812% |
| EPS 2 | -0.7500 | -0.6800 | -0.7800 | -0.8200 | -0.6500 | -0.7200 | -0.6700 | -0.7000 | -0.7000 | -0.6900 | -0.7746 | -0.8124 | -0.8480 | -0.8764 | -0.8450 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/9/21 | 2/28/22 | 5/9/22 | 8/8/22 | 11/8/22 | 3/9/23 | 5/9/23 | 8/9/23 | 11/9/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | 321 | 484 | 362 | 377 | 289 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -38.8 | -77.4 | -96.4 | -117 | -175 | -195 | -231 |
| ROE (net income / shareholders' equity) | - | - | -48.1% | -41% | -52.1% | -59.9% | -76.8% |
| ROA (Net income/ Total Assets) | - | - | -43.1% | -37.4% | -51.9% | -61.2% | -81.5% |
| Assets 1 | - | - | 285.9 | 431.4 | 387.7 | 392.9 | 332.4 |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex 1 | 1.53 | 1.95 | 1.76 | 0.92 | 0.2 | 1.98 | 2.43 |
| Capex / Sales | 3.66% | 25.79% | 18.17% | 58.29% | 12.97% | 33.97% | 72.98% |
| Announcement Date | 3/16/21 | 2/28/22 | 3/9/23 | 2/27/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
11.81
USD
Average target price
43
USD
Spread / Average Target
+264.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.79% | 712M | |
| +25.83% | 661B | |
| +26.67% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +14.63% | 231B | |
| +5.03% | 200B | |
| -9.08% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- PLRX Stock
- Financials Pliant Therapeutics, Inc.
